Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKTR-358 Single Dose in Healthy Volunteers
NCT04380324Phase 1Completed
- Sponsor
- Nektar Therapeutics
- Start
- Mar 2017
- Primary completion
- Jan 2019
- Modality
- Biologic, rProtein (Recombinant Protein), Polyethylene glycol conjugate
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE), atopic dermatitis (AD), alopecia areata and 1 more comparing LY3471851 with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Mar 2017; status: completed.
02
Drugs
rezpegaldesleukin
03
Conditions
systemic lupus erythematosus (SLE)atopic dermatitis (AD)alopecia areataautoimmune diseases
Beyond the preview
Go deeper on NCT04380324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04380324.